Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients
Source: Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients

Video Module

Watch this on-demand Webcast from the CCO AML satellite symposium at ASH 2017, featuring expert faculty Jeffrey E. Lancet, MD; Gail J. Roboz, MD; B. Douglas Smith, MD; and Roland B. Walter, MD, PhD, MS, as they discuss the most clinically relevant advances in treatment strategies for patients with AML.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify prognostic or therapeutically relevant molecular (genetic, epigenetic, protein) features or aberrations in AML and describe their clinical importance in terms of risk prediction, diagnosis, and prognosis
  • Summarize current evidence on the benefits of standard chemotherapy-based protocols and emerging therapies for the treatment of AML, including in elderly patients, those with relapsed/refractory disease, or patients with poor-risk cytogenetics
  • Discuss emerging safety and efficacy data and ongoing clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents for patients with AML who may not benefit from standard therapy
  • Discuss promising investigational treatments with patients with AML who may benefit from enrollment on clinical trials evaluating next-generation targeted agents, cytotoxics, epigenetic treatments, and immunotherapies

Topics covered include:

  • Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients
  • Managing Newly Diagnosed AML: Treatment Considerations to Personalize Care
  • Current Management of Relapsed Acute Myeloid Leukemia
  • Integrating Emerging Targeted Therapies Into AML Treatment Strategies
CCO Video Modules contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Program Directors

  • Jeffrey E. Lancet
    MD

Faculty

  • Gail J. Roboz
    MD
    B. Douglas Smith
    MD
    Roland B. Walter
    MD, PhD, MS

Credit Information

  • Release Date:
    January 31, 2018
  • Expiration Date:
    January 30, 2019
  • Physicians:
    maximum of 3.25 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Program Directors

Jeffrey E. Lancet, MD

Senior Member & Professor
Chair,
 Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Jeffrey E. Lancet, MD, has disclosed that he has received consulting fees from Bio-Path Holdings, BioSight, Celgene, Erytech, and Janssen and funds for research support from BioSight and Celgene.

 

Faculty

Gail J. Roboz, MD


Director, Clinical and Translational Leukemia Programs
Professor of Medicine
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has disclosed that she has received consulting fees from AbbVie, Amgen, Amphivena Therapeutics, Array BioPharma, Astex, Celgene, Celltrion, Genoptix, Janssen, MedImmune, Novartis, Pfizer, Sandoz, and Sunesis and funds for research support from Cellectis.
 

B. Douglas Smith, MD


Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

B. Douglas Smith, MD, has disclosed that he has received consulting fees from Ariad/Takeda, Celgene, Curis, Novartis, and Pfizer.
 

Roland B. Walter, MD, PhD, MS


Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Associate Professor of Medicine
Division of Hematology
Department of Medicine
University of Washington School of Medicine
Adjunct Associate Professor 
Department of Epidemiology
University of Washington School of Public Health
Seattle, Washington

Roland B. Walter, MD, PhD, MS, has disclosed that he has received consulting fees from Agios, Amphivena, Aptevo, BioLineRx, Covagen, Jazz, and Race Oncology; funds for research support from AbbVie, ADC Therapeutics, Amgen, Arog, Celator/Jazz, Covagen, Pharmacyclics, Seattle Genetics, and Stemline Therapeutics; and holds ownership interests with Amphivena.
 

Staff

Megan Cartwright, PhD


Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
 

Terrence Fagan, 


Associate Managing Editor

Terrence Fagan has no real or apparent conflicts of interest to report.
 

Timothy A. Quill, PhD


Senior Managing Editor

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.
 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with acute myeloid leukemia.


Goal

The goal of this activity is to help participants align their clinical practice with practice-changing findings and current guidelines for the treatment of acute myeloid leukemia.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify prognostic or therapeutically relevant molecular (genetic, epigenetic, protein) features or aberrations in AML and describe their clinical importance in terms of risk prediction, diagnosis, and prognosis
  • Summarize current evidence on the benefits of standard chemotherapy-based protocols and emerging therapies for the treatment of AML, including in elderly patients, those with relapsed/refractory disease, or patients with poor-risk cytogenetics
  • Discuss emerging safety and efficacy data and ongoing clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents for patients with AML who may not benefit from standard therapy
  • Discuss promising investigational treatments with patients with AML who may benefit from enrollment on clinical trials evaluating next-generation targeted agents, cytotoxics, epigenetic treatments, and immunotherapies
 

Physician Continuing Medical Education


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Astellas, Daiichi Sankyo, Jazz Pharmaceuticals, and Pfizer Inc..

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 3.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 31, 2018, through January 30, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.